Despite its clinical efficacy in certain hematologic cancers, the utility of ABT-263 may be hampered by on-target thrombocytopenia (Roberts et al., 2012) that is a result of BCL-xL inhibition in platelets (Mason et al., 2007). The gene discussed is BCL2L1; the disease is Thrombocytopenia.